• $102.5M
    Market Cap
  • 40.07%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
10/31/2022
Income Statement
Total Operating Revenue
149,149
N/A
N/A
N/A
23.4M
+31.51%
17.8M
+89.34%
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
149,149
N/A
0
-100.00%
12.7M
+55.99%
8.1M
+33.15%
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Depreciation and Amortization Expense
702,258
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
14.7M
+46.30%
10.1M
+55.82%
6.5M
+10.49%
5.9M
+46.92%
Operating Profit
-593,487
-94.45%
-10.7M
-351.44%
4.3M
+344.46%
957,149
+36.43%
Interest Income
179,731
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
-150,331
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
29,400
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
5.4M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Income before Taxes
4.8M
+145.19%
-10.7M
+1,515.05%
-662,320
-257.71%
419,951
+141.38%
Income Taxes
1.6M
-5.45%
1.7M
+357.18%
370,932
+51.18%
245,358
+62.98%
Extraordinary Items
0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
3.2M
+130.20%
-10.7M
+1,515.05%
-662,320
-257.71%
419,951
+141.38%
Net Income from Continuing Operations Applicable to Common
4.8M
+145.19%
-10.7M
+1,515.05%
-662,320
-257.71%
419,951
+141.38%
Basic EPS and Net Income
0.01
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Diluted EPS and Net Income
0.01
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Basic Weighted Average Shares
243.4M
N/A
N/A
N/A
172.7M
+2.08%
169.2M
+25.11%
Diluted Weighted Average Shares
250.9M
N/A
N/A
N/A
172.7M
N/A
N/A
N/A
Balance Sheet
Cash and Cash Equivalents
11.4M
+142.87%
4.7M
-31.19%
6.8M
+330.02%
1.6M
+42.04%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
11.4M
+142.87%
4.7M
-31.19%
6.8M
+330.02%
1.6M
+42.04%
Total Current Assets
22.2M
+7.37%
20.7M
+32.31%
15.6M
+97.38%
7.9M
+17.96%
Accumulated Depreciation
9.3M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
14.1M
+86,220.41%
16,283
-99.90%
16.6M
+29.52%
12.8M
+45.14%
Total Long-Term Assets
300,000
-93.97%
5.0M
+13.23%
4.4M
+17.35%
3.7M
-7.01%
Total Assets
62.7M
+44.84%
43.3M
+46.26%
29.6M
+80.91%
16.4M
+15.22%
Income Taxes Payable
296,018
N/A
N/A
N/A
507,332
+799.51%
56,401
-58.87%
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
5.7M
-71.33%
20.0M
+69.63%
11.8M
+121.41%
5.3M
+37.63%
Total Long-Term Debt
2.6M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
8.4M
+503.62%
1.4M
+147.84%
560,425
-21.67%
715,461
-41.63%
Total Liabilities
38.8M
+41.64%
27.4M
+68.29%
16.3M
+119.15%
7.4M
+4.85%
Retained Earnings
-41.6M
+26.54%
-32.8M
+61.38%
-20.4M
-195.30%
21.4M
+197.95%
Total Stockholders Equity
20.9M
N/A
N/A
N/A
13.3M
+49.13%
8.9M
+25.55%
Total Shares Outstanding
249.7M
N/A
N/A
N/A
182.0M
+6.67%
170.6M
+8.73%
Cash Flow
Cash from Operating Activities
3.6M
-49.89%
7.1M
+24.35%
5.7M
+185.87%
2.0M
+940.46%
Capital Expenditures
4.7M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
-6.9M
-43.68%
-12.2M
+322.47%
-2.9M
+159.35%
-1.1M
-59.18%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
9.8M
+230.40%
3.0M
-33.44%
4.4M
+1,149.32%
-422,541
-110.94%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
-397.92%
N/A
N/A
N/A
18.22%
+237.96%
5.39%
-27.94%
Return on Assets
6.09%
+120.77%
-29.33%
+918.35%
-2.88%
-204.87%
2.75%
+124.32%
Return on Equity
N/A
N/A
N/A
N/A
-5.95%
-213.73%
5.23%
+115.91%
Revenue Growth
N/A
N/A
N/A
N/A
31.51%
-64.73%
89.34%
-26.30%
Current Ratio
3.87
+274.43%
1.03
-21.99%
1.33
-10.86%
1.49
-14.29%
Cash Ratio
1.99
+747.08%
0.23
-59.44%
0.58
+94.19%
0.30
+3.22%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow